Emergent BioSolutions Inc.'s revenue has shrunk 10% a year over three years, and shrunk 15% a year over five. Revenue growth, 3-year annual rate: −10% (Drug Manufacturers - Specialty & Generic median +12%). Revenue growth, 5-year rate: −15%, growth has picked up over the last three years. Years of annual history on file: 17, FY2009 to FY2025, as filed.

EBSEmergent BioSolutions Inc.

Healthcare

$6.24-34% 1Y

$6.24

$4.4552 weeks$13.90

Is it growing?

Watch

Growth is fading: revenue shrinking (−10% year on year) and operating margin narrowing (−18.2 points).

2 to watch, 1 without data

Revenue trend−10% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −15% a year.

Margin direction−18.2 points operating

Trailing-twelve-month operating margin, -8.1% now against 10.2% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is EBS growing?

Emergent BioSolutions Inc.'s revenue has shrunk 10% a year over three years, and shrunk 15% a year over five.

−10%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −15%
Revenue growth, 5-year rate · −10% over three · growth has picked up over the last three years
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›